Expression of prostaglandin I2 (prostacyclin) receptor in blood of migraine patients: A potential biomarker

Kheirollahi, Majid; Kazemi, Mohammad; Mini, Gilda A; Khorvash, Fariborz; Ahangari, Fatemeh; Kolahdouz, Mahsa; Koulivand, Leila

Expression of prostaglandin I2 (prostacyclin) receptor in blood of migraine patients: A potential biomarker

Authors

¹ Department of Genetics and Molecular Biology, Pediatric Inherited Diseases Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Migraine is the most common chronic neurological disorders that may be associated with vasodilatation. According to the role of prostaglandin I2 (prostacyclin) receptor (PTGIR) in migraine as a receptor, which acts in vasodilatation, we decided to study the changes of PTGIR expression in migraine patients in relation to a suitable control group.
Materials and Methods: Extracted mRNA from lymphocytes of 50 cases and 50 controls was used to synthesize cDNA. Real-time polymerase chain reaction was performed, and the data were analyzed. Our results show that PTGIR mRNA expression in cases was significantly higher than the control group (P = 0.010).
Results: In conclusion, mRNA expression of PTGIR in the blood of people with migraines could be considered as a biomarker.
Conclusion: In addition, repression of PTGIR gene expression by methods such as using siRNA is probably suitable for therapy of migraine patients.

Keywords

References

1.	Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2 ^nd edition. Cephalalgia 2004;24 Suppl 1:9-160.
2.	Limmroth V, Michel MC. The prevention of migraine: A critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001;52:237-43.
3.	Piane M, Lulli P, Farinelli I, Simeoni S, De Filippis S, Patacchioli FR, et al. Genetics of migraine and pharmacogenomics: Some considerations. J Headache Pain 2007;8:334-9.
4.	Bartleson JD, Cutrer FM. Migraine update. Diagnosis and treatment. Minn Med 2010;93:36-41.
5.	Goadsby PJ. The vascular theory of migraine - A great story wrecked by the facts. Brain 2009;132:6-7.
6.	Brennan KC, Charles A. An update on the blood vessel in migraine. Curr Opin Neurol 2010;23:266-74.
7.	Dodick DW. Examining the essence of migraine - Is it the blood vessel or the brain? A debate. Headache 2008;48:661-7.
8.	Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011;412:671-87.
9.	Tanaka Y, Yamaki F, Koike K, Toro L. New insights into the intracellular mechanisms by which PGI2 analogues elicit vascular relaxation: Cyclic AMP-independent, Gs-protein mediated-activation of MaxiK channel. Curr Med Chem Cardiovasc Hematol Agents 2004;2:257-65.
10.	Boron WF, Boulpaep EL. Medical Physiology: A Cellular and Molecular Approaoch. Philadelphia: Elsevier/Saunders; 2005.
11.	Haynes J Jr, Robinson J, Saunders L, Taylor AE, Strada SJ. Role of cAMP-dependent protein kinase in cAMP-mediated vasodilation. Am J Physiol 1992;262:H511-6.
12.	Negash S, Gao Y, Zhou W, Liu J, Chinta S, Raj JU. Regulation of cGMP-dependent protein kinase-mediated vasodilation by hypoxia-induced reactive species in ovine fetal pulmonary veins. Am J Physiol Lung Cell Mol Physiol 2007;293:L1012-20.
13.	Kilfeather SA, Massarella A, Gorgolewska G, Ansell E, Turner P. Beta-adrenoceptor and epoprostenol (prostacyclin) responsiveness of lymphocytes in migraine patients. Postgrad Med J 1984;60:391-3.
14.	Puig-Parellada P, Planas JM, Giménez J, Sánchez J, Gaya J, Tolosa E, et al. Plasma and saliva levels of PGI2 and TXA2 in the headache-free period of classical migraine patients. The effects of nicardipine. Headache 1991;31:156-8.
15.	Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82.
16.	Ducros A, Tournier-Lasserve E, Bousser MG. The genetics of migraine. Lancet Neurol 2002;1:285-93.
17.	Stitham J, Arehart EJ, Gleim S, Douville K, MacKenzie T, Hwa J. Arginine (CGC) codon targeting in the human prostacyclin receptor gene (PTGIR) and G-protein coupled receptors (GPCR). Gene 2007;396:180-7.
18.	Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, et al. Roles of prostaglandin I (2) and thromboxane A (2) in cardiac ischemia-reperfusion injury: A study using mice lacking their respective receptors. Circulation 2001;104:2210-5.
19.	Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41.
20.	Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-7.
21.	Southall MD, Vasko MR. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 2001;276:16083-91.
22.	Wienecke T, Olesen J, Oturai PS, Ashina M. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 2008;139:106-16.
23.	Wienecke T, Olesen J, Ashina M. Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 2010;30:179-90.
24.	Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: Update. Curr Opin Neurol 2013;26:269-75.
25.	Antonova M. Prostaglandins and prostaglandin receptor antagonism in migraine. Dan Med J 2013;60:B4635.
26.	Myren M, Olesen J, Gupta S. Pharmacological and expression profile of the prostaglandin I (2) receptor in the rat craniovascular system. Vascul Pharmacol 2011;55:50-8.

Advanced Biomedical Research